Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Patients with metastatic malignant melanoma will receive CP-4055 200 mg/m2/day intravenously
(IV) on Day 1-5 every four weeks and sorafenib 400 mg b.i.d. (twice daily) every day until
complete response or disease worsening/progressing.